Skip to content
Open access

Ultrasound-Guided Minimally Invasive Tenotomy Utilizing TenJet for Recalcitrant Gluteal Tendinopathy: A Six-Month Interim Analysis From a Prospective Multicenter Study

Sep 2026 · Cureus · Vol 18 · 0 citations · 34 references
Medicine

Abstract

Background: Chronic gluteal tendinopathy is characterized by failed tendon healing, collagen disorganization, and breakdown in tendon structure. Traditional conservative management involves nonsteroidal anti-inflammatory drugs (NSAIDs), physical therapy, and corticosteroid injections. However, next steps for recalcitrant cases are lacking consensus. The TenJet device (HydroCision, Inc., North Billerica, Massachusetts, United States), utilizing high-pressure saline to resect degenerative tissue, offers a minimally invasive option to treat gluteal tendinopathy. Methods: From 2022 to 2025, 46 patients with gluteal tendinopathy refractory to conservative treatment were enrolled across multiple centers with planned 24-month follow-up. Visual Analog Scale (VAS) pain score and Victorian Institute of Sport Assessment-Gluteal Questionnaire (VISA-G) patient-reported outcomes were prospectively collected via REDCap alongside demographics, treatment history, procedural details, and adverse events. Results: The cohort was predominantly female (44/46, 95.6%), with a mean age of 60.7±8.44 years and a mean BMI of 26.9±4.73 kg/m². The mean VAS improved from 5.81±2.02 at baseline to 3.14±2.24 at two weeks (p<0.001), 2.40±2.00 at six weeks (p<0.001), 2.17±1.87 at three months (p<0.001), and 2.10±2.10 at six months (p<0.001). VISA-G improved from 44.9±14.3 at baseline to 49.0±19.1 at two weeks (p=0.807), 62.2±15.8 at six weeks (p<0.001), 66.9±15.2 at three months (p<0.001), and 69.6±12.6 at six months (p<0.001). One patient developed an adhesive-related rash; no device malfunctions or serious complications were observed. Conclusions: Ultrasound-guided minimally invasive tenotomy with TenJet was associated with significant, sustained reductions in pain and improvements in function through the six-month follow-up, with a favorable short-term safety profile for chronic gluteal tendinopathy refractory to conservative management.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.